SCHEMBL5135963

SCHEMBL5135963

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(C)Cc1ccc(CC)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.48
TSHR P16473 4/20 0.46
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GLA P06280 1/20 0.41
HSD11B1 P28845 2/20 0.40
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
NR1H3 Q13133 1/20 0.39
PDE4B Q07343 2/20 0.38
CYP3A4 P08684 2/20 0.37
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136921 0.91 C5AR1 (0.47) C5AR1TSHRLMNASMN1; SMN2MAPK1
SCHEMBL5135854 0.89 C5AR1 (0.46) C5AR1TSHRLMNASMN1; SMN2MAPK1
SCHEMBL5136179 0.89 CASR (0.46) C5AR1TSHRLMNASMN1; SMN2MAPK1
SCHEMBL5134746 0.89 C5AR1 (0.48) C5AR1TSHRLMNASMN1; SMN2MAPK1
SCHEMBL5137312 0.88 C5AR1 (0.48) C5AR1TSHRALDH1A1HSD11B1KDM4E
SCHEMBL5135106 0.87 C5AR1 (0.47) C5AR1TSHRALDH1A1HSD11B1KDM4E
SCHEMBL5072249 0.87 C5AR1 (0.47) C5AR1TSHRALDH1A1HSD11B1KDM4E
SCHEMBL5134917 0.84 C5AR1 (0.44) C5AR1TSHRALDH1A1HSD11B1KDM4E
SCHEMBL651094 0.83 TSHR (0.50) C5AR1TSHRLMNASMN1; SMN2MAPK1
SCHEMBL5136185 0.83 C5AR1 (0.44) C5AR1TSHRLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed